UMASS MEMORIAL MEDICAL CENTER
1. Target Overview & Investment Thesis
UMASS MEMORIAL MEDICAL CENTER is a 657-bed large academic medical center in WORCESTER, MA with $1.90B in net patient revenue and a -23.6% operating margin. The hospital serves a payer mix of 29.7% Medicare, 18.5% Medicaid, and 51.8% commercial.
Thesis: Undervalued. Our ML models identify $139.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -23.6% to -16.2% (+736bps).
| Net Revenue HCRIS | $1.90B |
| Current EBITDA COMPUTED | $-447.0M |
| Operating Margin COMPUTED | -23.6% |
| Occupancy HCRIS | 100.7% |
| Revenue / Bed COMPUTED | $2.9M |
| Net-to-Gross HCRIS | 29.5% |
| Distress Probability ML | 39.5% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -23.6% places it below the state median. Among 13 size-comparable peers (328-1314 beds), the median margin is -28.1%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (328-1314), prioritizing same-state peers. 13 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| UMASS MEMORIAL MEDICAL CENTER (Target) | MA | 657 | $1.90B | -23.6% |
| MASSACHUSETTS GENERAL HOSPITAL | MA | 997 | $3.50B | -44.9% |
| BRIGHAM AND WOMENS HOSPITAL | MA | 812 | $2.80B | -32.6% |
| BETH ISRAEL DEACONESS MEDICAL | MA | 705 | $1.67B | -38.9% |
| CHILDRENS HOSPITAL CORPORATION | MA | 485 | $1.59B | -27.2% |
| BAYSTATE MEDICAL CENTER | MA | 728 | $1.46B | -15.0% |
| BOSTON MEDICAL CENTER | MA | 440 | $1.19B | -50.0% |
| LAHEY CLINIC HOSPITAL INC. | MA | 345 | $991.1M | -4.2% |
| SOUTHCOAST HOSPITALS GROUP IN | MA | 641 | $845.4M | -16.0% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $139.7M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $39.8M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $38.0M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $37.6M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $23.1M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $1.2M | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-447.0M |
| + RCM Uplift | +$139.7M |
| Pro Forma EBITDA | $-307.3M |
| Current Margin | -23.6% |
| Pro Forma Margin | -16.2% |
| WC Released (1x) | $72.8M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-687.7M | $-1.55B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-687.7M | $-1.93B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-618.9M | $-1.69B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-618.9M | $-2.03B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-756.5M | $-2.03B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-756.5M | $-2.48B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 13 hospitals with 328-1314 beds
- Same-state prioritization (n=14)
- Comp margins: P25=-40.4% / P50=-28.1% / P75=-15.8%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.